Aggressive pituitary tumours and pituitary carcinomas
Although usually benign, anterior pituitary tumours occasionally exhibit aggressive
behaviour, with invasion of surrounding tissues, rapid growth, resistance to conventional …
behaviour, with invasion of surrounding tissues, rapid growth, resistance to conventional …
[HTML][HTML] Genetic and epigenetic drivers of neuroendocrine tumours (NET)
A Di Domenico, T Wiedmer, I Marinoni… - Endocrine-related …, 2017 - erc.bioscientifica.com
Neuroendocrine tumours (NET) of the gastrointestinal tract and the lung are a rare and
heterogeneous group of tumours. The molecular characterization and the clinical …
heterogeneous group of tumours. The molecular characterization and the clinical …
Tumor target amplification: Implications for nano drug delivery systems
K Seidi, HA Neubauer, R Moriggl… - Journal of controlled …, 2018 - Elsevier
Tumor cells overexpress surface markers which are absent from normal cells. These tumor-
restricted antigenic signatures are a fundamental basis for distinguishing on-target from off …
restricted antigenic signatures are a fundamental basis for distinguishing on-target from off …
[HTML][HTML] Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP
C Cullinane, K Waldeck, L Kirby, BE Rogers, P Eu… - Scientific reports, 2020 - nature.com
Peptide receptor radionuclide therapy (PRRT) is an important treatment option for patients
with somatostatin receptor-2 (SSTR2)-expressing neuroendocrine tumour (NET) though …
with somatostatin receptor-2 (SSTR2)-expressing neuroendocrine tumour (NET) though …
[HTML][HTML] Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer
MJ Klomp, SU Dalm, M De Jong, RA Feelders… - Reviews in Endocrine …, 2021 - Springer
Both somatostatin (SST) and somatostatin receptors (SSTRs) are proteins with important
functions in both physiological tissue and in tumors, particularly in neuroendocrine tumors …
functions in both physiological tissue and in tumors, particularly in neuroendocrine tumors …
Combination strategies to improve targeted radionuclide therapy
In recent years, targeted radionuclide therapy (TRT) has emerged as a promising strategy
for cancer treatment. In contrast to conventional radiotherapy, TRT delivers ionizing radiation …
for cancer treatment. In contrast to conventional radiotherapy, TRT delivers ionizing radiation …
[HTML][HTML] EANM position paper on the role of radiobiology in nuclear medicine
A Aerts, U Eberlein, S Holm, R Hustinx… - European journal of …, 2021 - Springer
With an increasing variety of radiopharmaceuticals for diagnostic or therapeutic nuclear
medicine as valuable diagnostic or treatment option, radiobiology plays an important role in …
medicine as valuable diagnostic or treatment option, radiobiology plays an important role in …
[HTML][HTML] Peptide receptor radionuclide therapy in thyroid cancer
S Gubbi, CA Koch, J Klubo-Gwiezdzinska - Frontiers in endocrinology, 2022 - frontiersin.org
The treatment options that are currently available for management of metastatic, progressive
radioactive iodine (RAI)-refractory differentiated thyroid cancers (DTCs), and medullary …
radioactive iodine (RAI)-refractory differentiated thyroid cancers (DTCs), and medullary …
[HTML][HTML] The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs)
MP Yavropoulou, M Tsoli, K Barkas… - Endocrine-Related …, 2020 - erc.bioscientifica.com
Non-functioning pituitary adenomas, recently alternatively termed pituitary neuroendocrine
tumours (NFpitNETs), are mostly benign neoplasms that are not associated with a hormonal …
tumours (NFpitNETs), are mostly benign neoplasms that are not associated with a hormonal …
Establishment of the first well-differentiated human pancreatic neuroendocrine tumor model
D Benten, Y Behrang, L Unrau, V Weissmann… - Molecular Cancer …, 2018 - AACR
Clinical options for systemic therapy of neuroendocrine tumors (NET) are limited.
Development of new drugs requires suitable representative in vitro and in vivo model …
Development of new drugs requires suitable representative in vitro and in vivo model …